News

Head/Neck Cancer Treatments Less Effective in HIV Patients

Publish date: January 26, 2012

 

FROM A HEAD AND NECK CANCER SYMPOSIUM BY THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY

Dr. Mourad and his nine coauthors declared that they had no financial disclosures.

Pages

Recommended Reading

Biomarkers May Improve Lung Cancer Screening
MDedge Hematology and Oncology
Glucarpidase Approved to Treat Methotrexate Toxicity
MDedge Hematology and Oncology
Regorafenib Anticipated to Show Survival Advantage in Colorectal Cancer
MDedge Hematology and Oncology
Less May Be More in Treating High-Risk Myeloma
MDedge Hematology and Oncology
U.S. Oncologists Confront Pressure to Curb Cancer Costs.
MDedge Hematology and Oncology
BRCA1/2 Mutations Tied to Better Ovarian Cancer Survival
MDedge Hematology and Oncology
Gastric Cancer Subtype May Affect Bevacizumab Benefit
MDedge Hematology and Oncology
Bevacizumab Boosts Treatment Responses in Early Breast Cancer
MDedge Hematology and Oncology
Oral HPV Infection More Prevalent in Men Than Women
MDedge Hematology and Oncology
Cancer Screening Falls Short of Federal Targets
MDedge Hematology and Oncology